Hepatitis C Phase 3 Trials Underway for TMC435
Medivir Announces New Studies in Phase III Program for TMC435
HUDDINGE, Sweden, March 13, 2012 /PRNewswire via COMTEX/ — Study in previous non-responder Hepatitis C genotype-1 infected patients
Study in Hepatitis C genotype-4 infected patients
MedivirAB (omx:MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.
Continue reading this entire article:
First Pediatric Triple Organ Transplant Saves Young Girl's Life
Egyptian Hep C Problem to Benefit from Better Test